Publications by authors named "A A Agyeman"
Novel and repurposed antiviral drugs are available for the treatment of coronavirus disease 2019 (COVID-19). However, antiviral combinations may be more potent and lead to faster viral clearance, but the methods for screening antiviral combinations against respiratory viruses are not well established and labor-intensive. Here, we describe a time-efficient (72-96 h) and simple drug-sensitivity assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using standard 96-well plates.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effects of molnupiravir on viral clearance, antibody response, and mutagenesis in non-hospitalized individuals within 5 days of experiencing COVID-19 symptoms, comparing it to usual care.
- Results show that while molnupiravir accelerates the decline of viral load, many participants still test positive for the virus 5 days later, and significantly lower antiviral antibodies are observed after 14 days compared to those receiving usual care.
- Serial sequencing suggests that treatment with molnupiravir leads to increased mutations of the virus, raising concerns about the emergence of potentially transmissible variants, indicating that the current treatment duration may be insufficient.
The US FDA convened a virtual public workshop with the goals of obtaining feedback on the terminology needed for effective communication of multicomponent biomarkers and discussing the diverse use of biomarkers observed across the FDA and identifying common issues. The workshop included keynote and background presentations addressing the stated goals, followed by a series of case studies highlighting FDA-wide and external experience regarding the use of multicomponent biomarkers, which provided context for panel discussions focused on common themes, challenges and preferred terminology. The final panel discussion integrated the main concepts from the keynote, background presentations and case studies, laying a preliminary foundation to build consensus around the use and terminology of multicomponent biomarkers.
View Article and Find Full Text PDFSARS-CoV-2 viral dynamic modeling to inform model selection and timing and efficacy of antiviral therapy.
CPT Pharmacometrics Syst Pharmacol
October 2023
Article Synopsis
- Mathematical models have been developed to track the viral load changes of SARS-CoV-2 in individuals, with eight existing models evaluated for their effectiveness.
- Data from a community study involving 2155 measurements from 162 patients revealed that an improved target-cell limited model, which accounts for an eclipse phase and immune response, best fits the observed viral load dynamics.
- Simulations using this model predicted the effectiveness of the antiviral tixagevimab-cilgavimab, aligning well with real clinical trial results, highlighting the importance of early and effective antiviral treatment for better outcomes.
Objective: Acute exacerbations of biofilm-associated Pseudomonas aeruginosa infections in cystic fibrosis (CF) have limited treatment options. Ceftolozane/tazobactam (alone and with a second antibiotic) has not yet been investigated against hypermutable clinical P. aeruginosa isolates in biofilm growth.
View Article and Find Full Text PDF